Before a full review, identify whether supplier evidence is already a commercial risk.
This intake helps determine whether a Brazilian supplier’s documentation, traceability, environmental records and buyer-facing evidence are ready for European procurement scrutiny.
Is the company facing a real evidence risk, or only general regulatory curiosity?
The intake exists to qualify the commercial situation. It identifies whether the company is exposed to a buyer, contract, procurement, compliance or documentation risk that justifies a structured Supplier Evidence Review.
Market exposure
Does the company export, supply, negotiate with or depend on buyers connected to the European market?
Evidence pressure
Has the buyer requested documentation, declarations, traceability, emissions-related data or supplier controls?
Commercial urgency
Is the request connected to revenue, contract renewal, onboarding, procurement approval or buyer qualification?
The first diagnostic is not a long report. It is a disciplined risk filter.
These are the core questions used to understand whether a supplier evidence problem is already material from a commercial standpoint.
Buyer exposure
Does the company currently sell to, negotiate with or target a European buyer, importer, distributor or supply chain?
Evidence request
Has the company received a buyer request involving traceability, environmental documentation, origin, emissions or supplier declarations?
Documentation location
Are the documents centralized and reviewable, or scattered across operations, ESG, legal, logistics, finance and third parties?
Buyer readability
Can non-Brazilian procurement, legal, compliance or sustainability teams understand the documents without internal explanation?
Contract pressure
Is the evidence issue connected to a contract, renewal, onboarding, supplier approval, tender or commercial deadline?
Regulatory trigger
Does the request mention or imply CBAM, EUDR, CSDDD, CSRD, Scope 3, product data, due diligence or audit requirements?
The intake classifies exposure before the company commits to a deeper review.
The goal is to avoid generic consulting. A company should move to a full review only when there is a real evidence gap, buyer pressure or commercial risk.
A supplier evidence issue becomes urgent when it is tied to revenue, buyer trust or procurement approval.
The intake looks for objective signals. The strongest signal is not regulatory curiosity. It is a concrete buyer request, deadline, contract clause, onboarding screen or commercial dependency.
The intake starts with facts, not a sales call.
The company sends a concise commercial and documentation snapshot. Villanova ESG uses it to determine whether the case deserves full review, limited triage or later monitoring.
No certification. No buyer approval promise. No free audit.
The intake is a qualification filter. It does not replace legal advice, audit assurance, certification, customs advice, financial advice or formal regulatory determination.
Not a certification
The intake does not certify suppliers, products, emissions, legal status, environmental performance or regulatory compliance.
Not a guarantee of acceptance
No intake or review can guarantee that a buyer, bank, auditor, authority or procurement team will accept specific documentation.
Not a full diagnosis
The intake only determines whether deeper review is justified. It does not replace the full Supplier Evidence Review.
Before committing to a full review, identify whether the evidence risk is real.
Send your company, sector, European buyer exposure and available documentation. Villanova ESG will assess whether a Supplier Evidence Review, limited triage or later monitoring is the right next step.